Deadline Alert: Tenax Therapeutics, Inc. Stockholders Face December 28, 2026 Lead Plaintiff Deadline in Securities Fraud Class Action, The Law Offices of Howard G. Smith Highlights

Class action on behalf of investors who bought Tenax Therapeutics, Inc. securities from November 13, 2023 through August 7, 2026 alleges the company failed to disclose key facts

BENSALEM, Pa.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. ("Tenax" or the "Company") (NASDAQ: TENX) investors who wish to serve as lead plaintiff in a pending securities fraud class action lawsuit must move the Court by December 28, 2026. The suit was filed on behalf of investors who purchased or otherwise acquired the Company's securities from November 13, 2023 through August 7, 2026, inclusive. The Law Offices of Howard G. Smith today highlighted the deadline in the case, Katz v. Tenax Therapeutics, Inc. et al., which was filed on October 26, 2026 in the U.S. District Court North Carolina Middle District (Case No. 1:26-cv-01264).

Investors with losses on Tenax Therapeutics, Inc. securities can reach The Law Offices of Howard G. Smith about the Tenax Therapeutics, Inc. lawsuit before the December 28, 2026 deadline to discuss potential claims under the federal securities laws.

Key deadline for Tenax Therapeutics, Inc. investors

• Deadline for lead plaintiff motions: December 28, 2026
• Class period: November 13, 2023 through August 7, 2026, inclusive
• Complaint filing date: October 26, 2026
• Court: U.S. District Court North Carolina Middle District

What happened?

On August 10, 2026, Tenax issued a press release reporting topline results from its Phase 3 LEVEL clinical trial. The press release stated that TNX-103 "did not meet its primary endpoint of improvement in the 6-minute walk distance versus placebo, or the key secondary endpoint of improvement in Kansas City Cardiomyopathy Questionnaire total symptom score."

On this news, Tenax's stock fell $12.06 per share, or 89.77%, to close at $1.38 per share on August 10, 2026, thereby injuring investors.

Allegations in the Tenax Therapeutics, Inc. case

The Tenax Therapeutics, Inc. shareholder lawsuit alleges that, throughout the class period, defendants made materially false and/or misleading statements and failed to disclose material adverse facts about Tenax Therapeutics, Inc.'s business, operations, and prospects. Specifically, the complaint alleges defendants failed to disclose to investors that: (1) TNX-103 was less effective than Defendants had led investors to believe; (2) accordingly, TNX-103's overall clinical, regulatory, and commercial prospects were overstated; and (3) as a result, defendants' positive statements about Tenax Therapeutics, Inc.'s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Tenax Therapeutics, Inc. investors who purchased or otherwise acquired securities during the class period may move the Court by December 28, 2026 to seek appointment as lead plaintiff in this putative class action.

"The lawsuit against Tenax Therapeutics, Inc. alleges that, among other things, the Company failed to tell investors that TNX-103 was less effective than Defendants had led investors to believe. Tenax Therapeutics, Inc. investors who bought during the class period may want to know their options before the December 28, 2026 lead plaintiff deadline passes," said Howard G. Smith of The Law Offices of Howard G. Smith.

Next steps for Tenax Therapeutics, Inc. investors

Tenax Therapeutics, Inc. investors who suffered losses may contact The Law Offices of Howard G. Smith to learn about pursuing their claims. Lead plaintiff motions in the Tenax Therapeutics, Inc. class action are due to the Court by December 28, 2026. For more information, visit the firm's website, email [e-mail], or call [phone].

To be a member of the Tenax Therapeutics, Inc. class, you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent class member. No class has been certified so far in the Tenax Therapeutics, Inc. case.

Common questions from Tenax Therapeutics, Inc. investors

Who is eligible? Investors who acquired Tenax Therapeutics, Inc. securities from November 13, 2023 through August 7, 2026 and suffered losses may qualify for the class in the Tenax Therapeutics, Inc. shareholder lawsuit.

What is the deadline? Lead plaintiff motions in the Tenax Therapeutics, Inc. case are due by December 28, 2026.

Can I still be part of the Tenax Therapeutics, Inc. class after the deadline? Yes, Tenax Therapeutics, Inc. investors who do not seek lead plaintiff appointment may remain class members.

Does it cost anything? The Law Offices of Howard G. Smith works on contingency, meaning Tenax Therapeutics, Inc. investors owe no attorneys' fees out of pocket. Any attorneys' fees and litigation expenses are paid solely from a recovery, if achieved, and require court approval.

About The Law Offices of Howard G. Smith

The Law Offices of Howard G. Smith has helped injured investors recover their money for more than 15 years. The firm prosecutes securities fraud, takeover, and derivative litigation against public companies and their officers, directors, and advisors in federal and state courts nationwide, and has helped clients recover hundreds of millions of dollars in losses. Clients speak directly with a lawyer, who will promptly answer any question.

Prior results do not guarantee a similar outcome.

Related links

• Tenax Therapeutics, Inc. case page, The Law Offices of Howard G. Smith
• Complaint: Katz v. Tenax Therapeutics, Inc. et al., U.S. District Court North Carolina Middle District
• Tenax Press Release
• Tenax Therapeutics, Inc. SEC filings index, EDGAR
• The Law Offices of Howard G. Smith

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.